Unknown

Dataset Information

0

Regulatory Molecules and Corresponding Processes of BCR-ABL Protein Degradation.


ABSTRACT: The BCR-ABL fusion protein with strong tyrosine kinase activity is one of the molecular biological bases of leukemia. Imatinib (Gleevec), a specific targeted drug for the treatment of chronic myeloid leukemia (CML), was developed for inhibiting the kinase activity of the BCR-ABL fusion protein. Despite the positive clinical efficacy of imatinib, the proportion of imatinib resistance has gradually increased. The main reason for the resistance is a decrease in sensitivity to imatinib caused by mutation or amplification of the BCR-ABL gene. In response to this phenomenon, the new generation of tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL fusion protein was developed to solve the problem. However this strategy only selectively inhibits the tyrosine kinase activity of the BCR-ABL protein without eliminating the BCR-ABL protein, it does not fundamentally cure the BCR-ABL-positive leukemia patients. With the accumulation of the knowledge of cellular molecular biology, it has become possible to specifically eliminate certain proteins by cellular proteases in a specific way. Therefore, the therapeutic strategy to induce the degradation of the BCR-ABL fusion protein is superior to the strategy of inhibiting its activity. The protein degradation strategy is also a solution to the TKI resistance caused by different BCR-ABL gene point mutations. In order to provide possible exploration directions and clues for eliminating the BCR-ABL fusion protein in tumor cells, we summarize the significant molecules involved in the degradation pathway of the BCR-ABL protein, as well as the reported potent compounds that can target the BCR-ABL protein for degradation.

SUBMITTER: Zhu HQ 

PROVIDER: S-EPMC6584333 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

Regulatory Molecules and Corresponding Processes of BCR-ABL Protein Degradation.

Zhu Han-Qing HQ   Gao Feng-Hou FH  

Journal of Cancer 20190602 11


The BCR-ABL fusion protein with strong tyrosine kinase activity is one of the molecular biological bases of leukemia. Imatinib (Gleevec), a specific targeted drug for the treatment of chronic myeloid leukemia (CML), was developed for inhibiting the kinase activity of the BCR-ABL fusion protein. Despite the positive clinical efficacy of imatinib, the proportion of imatinib resistance has gradually increased. The main reason for the resistance is a decrease in sensitivity to imatinib caused by mut  ...[more]

Similar Datasets

| S-EPMC6518887 | biostudies-literature
| S-EPMC5543464 | biostudies-literature
| S-EPMC4733637 | biostudies-literature
| S-EPMC5352360 | biostudies-literature
| S-EPMC6908937 | biostudies-literature
| S-EPMC5270248 | biostudies-literature
| S-EPMC3832611 | biostudies-literature
| S-EPMC7780059 | biostudies-literature
| S-EPMC5641955 | biostudies-literature
| S-EPMC5546432 | biostudies-literature